Advances in omalizumab treatment for IgE-mediated food allergies
The increasing prevalence of food allergies significantly affects both the physical and mental health of patients, while concurrently imposing a substantial economic burden on a global scale. Immunoglobulin E (IgE)-mediated food allergies typically manifest as acute reactions and may lead to severe...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shanghai Chinese Clinical Medicine Press Co., Ltd.
2025-08-01
|
| Series: | Zhongguo Linchuang Yixue |
| Subjects: | |
| Online Access: | https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20241062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222990703624192 |
|---|---|
| author | Siqi WANG Ling YE Meiling JIN |
| author_facet | Siqi WANG Ling YE Meiling JIN |
| author_sort | Siqi WANG |
| collection | DOAJ |
| description | The increasing prevalence of food allergies significantly affects both the physical and mental health of patients, while concurrently imposing a substantial economic burden on a global scale. Immunoglobulin E (IgE)-mediated food allergies typically manifest as acute reactions and may lead to severe allergic responses. Previous treatment strategies have been predominantly centered on allergen avoidance and oral immunotherapy (OIT), resulting in augmented economic and psychological burdens. In recent years, omalizumab, the anti-IgE monoclonal antibody, has emerged as a treatment option, either as monotherapy or in combination with OIT, for patients with IgE-mediated food allergies. Omalizumab holds promise in augmenting allergen tolerance, accelerating desensitization processes, and mitigating adverse effects associated with OIT. Nonetheless, a multitude of unresolved inquiries persist concerning the practical applications of omalizumab, necessitating additional real world studies for clarification. |
| format | Article |
| id | doaj-art-14de0bcfed6c4c38b06a7b799fbfa975 |
| institution | Kabale University |
| issn | 1008-6358 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Shanghai Chinese Clinical Medicine Press Co., Ltd. |
| record_format | Article |
| series | Zhongguo Linchuang Yixue |
| spelling | doaj-art-14de0bcfed6c4c38b06a7b799fbfa9752025-08-26T01:29:39ZengShanghai Chinese Clinical Medicine Press Co., Ltd.Zhongguo Linchuang Yixue1008-63582025-08-0132467568410.12025/j.issn.1008-6358.2025.2024106220241062Advances in omalizumab treatment for IgE-mediated food allergiesSiqi WANG0Ling YE1Meiling JIN2Department of Allergy, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Allergy, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Allergy, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaThe increasing prevalence of food allergies significantly affects both the physical and mental health of patients, while concurrently imposing a substantial economic burden on a global scale. Immunoglobulin E (IgE)-mediated food allergies typically manifest as acute reactions and may lead to severe allergic responses. Previous treatment strategies have been predominantly centered on allergen avoidance and oral immunotherapy (OIT), resulting in augmented economic and psychological burdens. In recent years, omalizumab, the anti-IgE monoclonal antibody, has emerged as a treatment option, either as monotherapy or in combination with OIT, for patients with IgE-mediated food allergies. Omalizumab holds promise in augmenting allergen tolerance, accelerating desensitization processes, and mitigating adverse effects associated with OIT. Nonetheless, a multitude of unresolved inquiries persist concerning the practical applications of omalizumab, necessitating additional real world studies for clarification.https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20241062food allergyimmunoglobulin eomalizumaboral immunotherapy |
| spellingShingle | Siqi WANG Ling YE Meiling JIN Advances in omalizumab treatment for IgE-mediated food allergies Zhongguo Linchuang Yixue food allergy immunoglobulin e omalizumab oral immunotherapy |
| title | Advances in omalizumab treatment for IgE-mediated food allergies |
| title_full | Advances in omalizumab treatment for IgE-mediated food allergies |
| title_fullStr | Advances in omalizumab treatment for IgE-mediated food allergies |
| title_full_unstemmed | Advances in omalizumab treatment for IgE-mediated food allergies |
| title_short | Advances in omalizumab treatment for IgE-mediated food allergies |
| title_sort | advances in omalizumab treatment for ige mediated food allergies |
| topic | food allergy immunoglobulin e omalizumab oral immunotherapy |
| url | https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20241062 |
| work_keys_str_mv | AT siqiwang advancesinomalizumabtreatmentforigemediatedfoodallergies AT lingye advancesinomalizumabtreatmentforigemediatedfoodallergies AT meilingjin advancesinomalizumabtreatmentforigemediatedfoodallergies |